Document made available to the pharmacist to communicate a drug interaction to the doctor.DOWNLOAD
Sofosbuvir / Velpatasvir may inhibit hepatic transports OATP1B1/B3 and BCRP and increase plasma concentration of Rosuvastatin.
Sofosbuvir : P-gp, BCRP / Velpastasvir : P-gp, BCRP, OATP1B1/1B3, CYP 2B6, 2C8, 3A4 (in vitro)
Velpastasvir : P-gp, BCRP, OATP1B1/1B3
OATP1B1, OATP1B3 and BCRP
Possible increased risk of HMG CoA inhibitor toxicity.
Start with a small dosage. Monitor closely for signs and symptoms of toxicity and adjust dosage as a function of efficacy and tolerance.
We do not recommend more than 10 mg per day.
Symptoms of toxicity associated with hypolipidemic agents : gastrointestinal effects, fatigue and muscular weaknesses, myalgias, muscular cramps, myopathies, rhabdomyolysis and myoglobinuria leading to renal insufficiency.
|100 mg *|
|+ 169% (2.7x)|
|+ 161% (2.6x)|
Ref #3250 : * This study was conducted with velpatasvir alone but no significant interaction is anticipated with sofosbuvir. The effects on velpatasvir have not been studied but no significant change is anticipated.